Search clinical trials for: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified

Total 45 results

Grifols Therapeutics LLC

Completed

Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency

Primary Immunodeficiency

United States, Canada
Grifols Therapeutics LLC

Completed

A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency

Primary Immunodeficiency

United States
Grifols Therapeutics LLC

Completed

An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human)

Rabies

United States
Grifols Therapeutics LLC

Completed

Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP

Purpura, Thrombocytopenic, Idiopathic

United States
Grifols Therapeutics LLC

Completed

Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients

Common Variable Immunodeficiency | Severe Combined Immunodeficiency | Wiskott-Aldrich Syndrome | Agammaglobulinemia | Immunologic Deficiency Syndrome

Canada, United States
Beth Israel Deaconess Medical Center
Grifols Biologicals, LLC

Terminated

The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes

Diabetes Mellitus | Diabetes Complications | Diabetic Neuropathies

United States
Grifols Therapeutics LLC

Completed

Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency

Primary Immunodeficiency

Spain, France, Germany, United Kingdom, Australia, Czechia, Hungary, Poland, Sweden
Grifols Therapeutics LLC

Completed

Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration

Macular Degeneration

Germany
Grifols Therapeutics LLC

Completed

Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (ICE)

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

United States, Israel, Germany, Czech Republic, Mexico, Argentina, Canada, Italy, Poland, Serbia
Grifols Therapeutics LLC

Completed

Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis (PRIVIG)

Multiple Sclerosis, Relapsing-Remitting

Canada, Israel, United States, Austria, Czech Republic, Germany, Greece, Hungary, Poland, Slovakia, Sweden, United Kingdom
Baxalta now part of Shire

Completed

Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

Primary Immunodeficiency Diseases (PID)

United States
Baxalta now part of Shire

Completed

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

Primary Immunodeficiency Diseases (PID)

United States
Baxalta now part of Shire

Completed

Phase 2/3 Study of IGSC, 20% in PIDD

Primary Immunodeficiency Diseases (PID)

United States, Canada
Baxalta now part of Shire

Terminated

Phase 3 IGIV, 10% in Alzheimer´s Disease

Alzheimer´s Disease

United States, Poland, United Kingdom, Belgium, Spain, Japan, Canada, Australia
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants

Healthy Volunteers

United States
Biotest Pharmaceuticals Corporation

Completed

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

Liver Cirrhosis | Hepatitis, Viral, Human | Hepatocellular Carcinoma | Hepatitis C Infection | Viruses

United States
Baxalta now part of Shire

Completed

Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects

Primary Immunodeficiency Diseases (PID)

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%

Kidney Failure, Chronic

United States
Green Cross Corporation
Atlantic Research Group

Recruiting

Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency

Primary Immune Deficiency

United States
ADMA Biologics, Inc.

Completed

Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)

Primary Immune Deficiency Disorders (PIDD)

United States
Baxalta now part of Shire
Alzheimer's Disease Cooperative Study (ADCS)

Completed

A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease

Alzheimer´s Disease

United States, Canada
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia

Exposure During Pregnancy

Poland, Czechia, United States, Germany, Slovakia
University of Chicago
Sunnybrook Health Sciences Centre; University of British Columbia; University... and other collaborators

Completed

Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage

Abortion, Habitual | Miscarriage, Recurrent

United States
Takeda
Takeda Development Center Americas, Inc.

Recruiting

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

Primary Immunodeficiency Diseases (PID)

United States
Baxalta now part of Shire

Completed

Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders

Primary Immunodeficiency Diseases (PID) | Immune Thrombocytopenic Purpura (ITP) | Kawasaki Syndrome

United States
Baxalta now part of Shire

Terminated

Long-Term Study of IGIV, 10% in Alzheimer´s Disease

Alzheimer´s Disease

United States
Inova Health Care Services
CSL Behring

Withdrawn

IVIG in Acute Ischemic Stroke: A Pilot Study (IVIG/AIS)

Ischemic Stroke

United States
Green Cross Corporation
Parexel; Atlantic Research Group

Completed

Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency

Immunologic Deficiency Syndromes

Canada, United States
Biotest
Syneos Health

Completed

Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID

Primary Immunodeficiency Disease

United States, Germany, Hungary, Russian Federation, Spain
Baxalta now part of Shire

Completed

Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy

Multifocal Motor Neuropathy

United States, Canada, Denmark
Sanofi Pasteur, a Sanofi Company

Completed

Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults

Rabies (Healthy Volunteers)

France
Baxalta now part of Shire

Completed

Immune Globulin Subcutaenous (Human), 20%

Primary Immunodeficiency Diseases (PID)

Germany, Austria, Hungary, Sweden, United Kingdom
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Completed

A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

United States, Israel, Canada, Spain, Czechia, Croatia, Poland, Italy, Serbia, Germany, Argentina, Mexico, Turkey, United Kingdom, Brazil, France, Greece, Slovakia, Colombia, Denmark, Norway, Sweden
Baxalta now part of Shire

Completed

Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura

Immune Thrombocytopenic Purpura (ITP)

Poland, Hungary, Germany, Czechia
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Completed

Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Spain, Canada, Poland, Italy, Serbia, Germany, Mexico, Turkey, United Kingdom, Czechia, France, United States, Argentina, Brazil, Colombia, Denmark, Greece, Slovakia
Crucell Holland BV

Completed

Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults

Rabies

India
Baxalta now part of Shire

Completed

Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)

Primary Immunodeficiency Diseases (PID) | Hypogammaglobulinemia | Agammaglobulinemia

Finland, Sweden
Takeda

Active, not recruiting

A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants

Primary Immunodeficiency Diseases (PID)

Japan
Takeda

Completed

A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)

Primary Immunodeficiency Diseases (PID)

Japan
Takeda

Active, not recruiting

A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Multifocal Motor Neuropathy (MMN)

Japan
Green Cross Corporation

Completed

An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia

Immune Thrombocytopenia

Korea, Republic of
Baxalta now part of Shire

Completed

Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID

Primary Immunodeficiency Diseases (PID)

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Takeda

Recruiting

IVIG for Infection Prevention After CAR-T-Cell Therapy

Lymphoma

United States
University of Colorado, Denver
Children's Hospital Los Angeles

Recruiting

Therapies for Down Syndrome Regression Disorder

Down Syndrome | Regression

United States
Weill Cornell Medical College in Qatar
University of Hull; Hamad Medical Corporation; Sidra Medical and Research Center

Active, not recruiting

HbA1c Variability in Type II Diabetes

Diabetes Mellitus Type 2

Qatar

Search clinical trials for: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations